| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Elizabeth M Mudge, Susan J Murch, Paula N Brow. Leaner and greener analysis of cannabinoids. Analytical and bioanalytical chemistry. vol 409. issue 12. 2018-03-09. PMID:28233028. |
the objective of this work was to develop and validate an accurate method for analyzing cannabinoids in cannabis raw materials and finished products that is more efficient and uses fewer toxic solvents. |
2018-03-09 |
2023-08-13 |
Not clear |
| Elizabeth M Mudge, Susan J Murch, Paula N Brow. Leaner and greener analysis of cannabinoids. Analytical and bioanalytical chemistry. vol 409. issue 12. 2018-03-09. PMID:28233028. |
an hplc-dad method was developed for eight cannabinoids in cannabis flowers and oils using a statistically guided optimization plan based on the principles of green chemistry. |
2018-03-09 |
2023-08-13 |
Not clear |
| Mark R Heckle, Mannu Nayyar, Scott E Sinclair, Karl T Webe. Cannabinoids and Symptomatic Bradycardia. The American journal of the medical sciences. vol 355. issue 1. 2018-03-01. PMID:29289259. |
cannabinoids, the bioactive components of marijuana, have adverse cardiovascular consequences, including symptomatic sinus bradycardia, sinus arrest and ventricular asystole. |
2018-03-01 |
2023-08-13 |
Not clear |
| Ghorbangol Ashabi, Mitra-Sadat Sadat-Shirazi, Solmaz Khalifeh, Laleh Elhampour, Mohammad-Reza Zarrindas. NMDA receptor adjusted co-administration of ecstasy and cannabinoid receptor-1 agonist in the amygdala via stimulation of BDNF/Trk-B/CREB pathway in adult male rats. Brain research bulletin. vol 130. 2018-02-22. PMID:28167133. |
consumption of cannabinoid receptor-1 (cb-1) agonist such as cannabis is widely taken in 3,4- methylenedioxymethamphetamine (mdma) or ecstasy users; it has been hypothesized that co-consumption of cb-1 agonist might protect neurons against mdma toxicity. |
2018-02-22 |
2023-08-13 |
rat |
| Percy Bondallaz, Bernard Favrat, Haïthem Chtioui, Eleonora Fornari, Philippe Maeder, Christian Girou. Cannabis and its effects on driving skills. Forensic science international. vol 268. 2018-02-21. PMID:27701009. |
traffic policies show growing concerns about driving under the influence of cannabis, since cannabinoids are one of the most frequently encountered psychoactive substances in the blood of drivers who are drug-impaired and/or involved in accidents, and in the context of a legalization of medical marijuana and of recreational use. |
2018-02-21 |
2023-08-13 |
Not clear |
| Susan R B Weiss, Katia D Howlett, Ruben D Bale. Building smart cannabis policy from the science up. The International journal on drug policy. vol 42. 2018-02-21. PMID:28189459. |
here, we review the state of the science on cannabis and cannabinoid health effects, both adverse and therapeutic. |
2018-02-21 |
2023-08-13 |
Not clear |
| Susan R B Weiss, Katia D Howlett, Ruben D Bale. Building smart cannabis policy from the science up. The International journal on drug policy. vol 42. 2018-02-21. PMID:28189459. |
we focus on the prevalence of use in different populations, the mechanisms by which cannabis exerts its effects (i.e., via the endocannabinoid system), and the double-edged potential of this system to inspire new medications, on one hand, and to cause short and long term harmful effects on the other. |
2018-02-21 |
2023-08-13 |
Not clear |
| Norbert Scherbaum, F Schifano, Udo Bonne. New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services. Pharmacopsychiatry. vol 50. issue 3. 2018-02-19. PMID:28444659. |
indeed, different from cannabis, synthetic cannabinoid users may present with epileptic seizures, loss of consciousness, and a range of persisting psychopathological disorders. |
2018-02-19 |
2023-08-13 |
Not clear |
| Michelle Taylor, Rosie Lees, Graeme Henderson, Anne Lingford-Hughes, John Macleod, John Sullivan, Matthew Hickma. Comparison of cannabinoids in hair with self-reported cannabis consumption in heavy, light and non-cannabis users. Drug and alcohol review. vol 36. issue 2. 2018-02-14. PMID:27296783. |
comparison of cannabinoids in hair with self-reported cannabis consumption in heavy, light and non-cannabis users. |
2018-02-14 |
2023-08-13 |
Not clear |
| Sabrina Giacoppo, Placido Bramanti, Emanuela Mazzo. Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation. Multiple sclerosis and related disorders. vol 17. 2018-02-07. PMID:29055461. |
to date, sativex, an oromucosal spray containing tetrahydrocannabinol and cannabidiol in approximately 1:1 ratio, is the only commercially available formulation containing cannabinoids used as add-on therapy for treatment of spasticity in adult ms patients who are not responding to conventional antispastic therapies. |
2018-02-07 |
2023-08-13 |
Not clear |
| Francesca Indorato, Aldo Liberto, Caterina Ledda, Guido Romano, Nunziata Barber. The therapeutic use of cannabinoids: Forensic aspects. Forensic science international. vol 265. 2018-02-06. PMID:27038587. |
since 2013 in the italian market has been introduced the nabiximols, a drug containing two of the main active cannabinoids: Δ(9)-tetrahydrocannabinol (Δ(9)-thc) and cannabidiol (cbd). |
2018-02-06 |
2023-08-13 |
Not clear |
| Virginia Brighenti, Federica Pellati, Marleen Steinbach, Davide Maran, Stefania Benvenut. Development of a new extraction technique and HPLC method for the analysis of non-psychoactive cannabinoids in fibre-type Cannabis sativa L. (hemp). Journal of pharmaceutical and biomedical analysis. vol 143. 2018-02-02. PMID:28609672. |
development of a new extraction technique and hplc method for the analysis of non-psychoactive cannabinoids in fibre-type cannabis sativa l. (hemp). |
2018-02-02 |
2023-08-13 |
Not clear |
| Virginia Brighenti, Federica Pellati, Marleen Steinbach, Davide Maran, Stefania Benvenut. Development of a new extraction technique and HPLC method for the analysis of non-psychoactive cannabinoids in fibre-type Cannabis sativa L. (hemp). Journal of pharmaceutical and biomedical analysis. vol 143. 2018-02-02. PMID:28609672. |
the present work was aimed at the development and validation of a new, efficient and reliable technique for the analysis of the main non-psychoactive cannabinoids in fibre-type cannabis sativa l. (hemp) inflorescences belonging to different varieties. |
2018-02-02 |
2023-08-13 |
Not clear |
| Jessica M Sido, Austin R Jackson, Prakash S Nagarkatti, Mitzi Nagarkatt. Marijuana-derived Δ-9-tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation. Journal of molecular medicine (Berlin, Germany). vol 94. issue 9. 2018-02-01. PMID:27038180. |
∆(9)-tetrahydrocannabinol (thc) is one of the major bioactive cannabinoids derived from the cannabis sativa plant and is known for its anti-inflammatory properties. |
2018-02-01 |
2023-08-13 |
mouse |
| C Hasenoehrl, U Taschler, M Storr, R Schich. The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. vol 28. issue 12. 2018-01-31. PMID:27561826. |
today, our knowledge of the ingredients of the cannabis plant has remarkably advanced enabling us to use a variety of herbal and synthetic cannabinoid (cb) compounds to study the endocannabinoid system (ecs), a physiologic entity that controls tissue homeostasis with the help of endogenously produced cbs and their receptors. |
2018-01-31 |
2023-08-13 |
human |
| Alexander F Hoffman, Matthew D Lycas, Jakub R Kaczmarzyk, Charles E Spivak, Michael H Baumann, Carl R Lupic. Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ Addiction biology. vol 22. issue 2. 2018-01-30. PMID:26732435. |
disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'spice' compounds: comparison with Δ there has been a marked increase in the availability of synthetic drugs designed to mimic the effects of marijuana. |
2018-01-30 |
2023-08-13 |
Not clear |
| Alexander F Hoffman, Matthew D Lycas, Jakub R Kaczmarzyk, Charles E Spivak, Michael H Baumann, Carl R Lupic. Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ Addiction biology. vol 22. issue 2. 2018-01-30. PMID:26732435. |
in vitro studies suggest that synthetic cannabinoids in these preparations are potent agonists at central cannabinoid cb1 receptors (cb1rs), but few investigations have delineated their cellular effects, particularly in comparison with the psychoactive component of marijuana, Δ |
2018-01-30 |
2023-08-13 |
Not clear |
| Martin A Katzman, Melissa Furtado, Leena Anan. Targeting the Endocannabinoid System in Psychiatric Illness. Journal of clinical psychopharmacology. vol 36. issue 6. 2018-01-26. PMID:27811555. |
however, one must consider all potential limitations when determining the safety and tolerability of cannabinoid products, specifically cannabinoid content (ie, Δ-tetrahydrocannabinol vs cannabidiol) as well as study design. |
2018-01-26 |
2023-08-13 |
Not clear |
| Maria Andersson, Karl B Scheidweiler, Cristina Sempio, Allan J Barnes, Marilyn A Huesti. Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips. Analytical and bioanalytical chemistry. vol 408. issue 23. 2018-01-25. PMID:27422645. |
this method is being used in a controlled cannabis administration study, investigating urine cannabinoid markers documenting recent cannabis use, chronic frequent smoking, or route of drug administration and potentially improving urine cannabinoid result interpretation. |
2018-01-25 |
2023-08-13 |
human |
| Shirley Alteba, Nachshon Korem, Irit Akira. Cannabinoids reverse the effects of early stress on neurocognitive performance in adulthood. Learning & memory (Cold Spring Harbor, N.Y.). vol 23. issue 7. 2018-01-17. PMID:27317195. |
here we examined whether cannabinoids administered during "late adolescence" (extensive cannabis use in humans at the ages 18-25) could reverse the long-term adverse effects of es on neurocognitive function in adulthood. |
2018-01-17 |
2023-08-13 |
rat |